Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2025-07 · 1880 (3) · 189310
DOI: 10.1016/j.bbcan.2025.189310 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025-07. Verfasst von Weijing Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Sorafenib, Liver Neoplasms, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 224 Literaturangaben. Gefördert von: Taishan Scholar Project of Shandong Province, National Natural Science Foundation of China, Shandong Province Natural Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains one of the most prevalent and lethal cancers globally. While surgical resection and liver transplantation offer potential cures for early-stage HCC, the majority of patients are diagnosed at advanced stages where such interventions are not viable. Sorafenib, a multi-target kinase inhibitor, has been a cornerstone in the treatment of advanced HCC since its approval in 2007. Despite its significant clinical impact, less than half of the treated patients derive long-term benefits due to the emergence of resistance and associated side effects. This review focuses on the role of sorafenib, an FDA-approved multi-target kinase inhibitor, in treating advanced HCC, discusses the mechanisms underlying its therapeutic effects and associated resistance, and explores additional therapeutic strategies being investigated to improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…
- Department of Cardiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China.
- Department of Cardiology, Zhongnan Hospital of Wuhan University, School of Pharmaceutical Sciences, Wuhan University, Wuhan 430071, China; Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Instit…
- Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China. Electronic address: xdzeng@baridd.ac.cn.
Förderung
- Taishan Scholar Project of Shandong Province
- National Natural Science Foundation of China
- Shandong Province Natural Science Foundation
Zitieren
APA
Zhang, W., Hong, X., Xiao, Y., Wang, H., & Zeng, X. (2025). Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1880(3), 189310. https://doi.org/10.1016/j.bbcan.2025.189310
Vancouver
Zhang W, Hong X, Xiao Y, Wang H, Zeng X. Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(3):189310. doi:10.1016/j.bbcan.2025.189310
BibTeX
@article{Zhang2025,
author = {Zhang, Weijing and Hong, Xuechuan and Xiao, Yuling and Wang, Hongbo and Zeng, Xiaodong},
title = {Sorafenib resistance and therapeutic strategies in hepatocellular carcinoma},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2025},
volume = {1880},
number = {3},
pages = {189310},
doi = {10.1016/j.bbcan.2025.189310}
}
EUVIMED